Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Fefer, Alexander ^a   Robinson, Nanette ^b   Benyunes, Mark C ^b   Bensinger, William I ^b   Press, Oliver ^b   Thompson, John A ^b   Lindgren, Catherine ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

Interleukin 2; Leukemia; Lymphoma; Marrow transplantation

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HYPOTENSION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INFANT; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; RECOMBINANT PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031416082     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Benyunes MC, Massumoto C, York A et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993;12: 159-163.
2. Benyunes MC, Higuchi C, York A et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-288.
3. Higuchi CM, Thompson JA, Cox T et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989;49: 5509-5513.
4. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561-2568.
5. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994;13:311-316.
6. Robinson N, Benyunes MC, Thompson JA et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997;19:435-442.
7. Thompson JA, Lee DJ, Lindgren CG et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989;49:235-240.
8. Thompson JA, Lee DJ, Lindgren CG et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-678.
9. Fefer A, Benyunes MC, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993:20 [suppl 9]:41-45.
10. Fefer A, Benyunes MC, York A et al. Use of interleukin-2 after bone marrow transplantation. In: Champlin R, Gale RP, eds. Advances and Controversies in Bone Marrow Transplantation. Bone Marrow Transplant 1995;15[suppl 1]:162-166.
11. Fefer A, Robinson N, Benyunes MC et al. Interleukin-2 after autologous blood or marrow transplantation. In: Dicke KA, Keating A, eds. Proceedings of the Eighth International Symposium on Autologous Marrow and Blood Transplantation; August 8-21, 1996; Arlington, TX; Charlottesville, VA: Carden Jennings; in press.
12. Petersen FB, Lynch MH, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993;11:1353-1360.
13. Robinson NR, Sanders JE, Benyunes MC et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996;87: 1249-1254.
14. Oshimi K, Oshimi Y, Akutsu M et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986;68:938-948.
15. Maraninchi D, Biaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78:2182-2187.
16. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994;83: 2081-2085.
17. Benyunes M, Fefer A. Interleukin-2 in the treatment of hematologic malignancies. In: Atkins M, Mier J, eds. Therapeutic Applications of Interleukin-2. New York: Marcel Dekker, 1993; 163-175.
18. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994;84:2158-2163.
19. Meloni G, Vignetti M, Andrizzi C et al. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma 1996;21:429-435.
20. Allavena P, Damia G, Colombo T et al. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol 1989;120:250-258.
21. Mazumder A. Experimental evidence of interleukin-2 activity in bone marrow transplantation. Cancer J Sci Am 1997;3[suppl 1]: S37-S42.
22. Gottlieb DJ, Brenner MK, Heslop HE et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989;60:610-615.
23. Heslop HE, Duncombe AS, Reittie JE et al. Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc 1991;23:1704-1705.
24. Blaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990;76:1092-1097.
25. Attal M, Biaise D, Marit G et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation - BGMT Group. Blood 1995;86:1619-1628.
26. Malkovsky M, Brenner MK, Hunt R et al. T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol 1986; 103:476-480.
27. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy [abstract]. Cancer Invest 1992;10:19-26.
28. Truitt RL, Johnson BD. Graft-versus-host disease and the graft-versus-leukemia effect: lessons from allogeneic bone marrow transplantation. In: Spitzer TR, Mazumder A, eds. Immunotherapy and Bone Marrow Transplantation. Armonk, NY: Futura, 1995;1.
29. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Nad Acad Sci U S A 1990;87:5633-5637.
30. Sznol M, Parkinson DR. Interleukin-2 in therapy of hematologic malignancies [editorial]. Blood 1994;83:2020-2022.
31. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664-672.
32. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-2130.
33. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
34. Soiffer RJ, Murray C, Gonin R et al. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994;84:964-971.